Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Ultragenyx Pharmaceutical Inc. RARE

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.


Recent & Breaking News (NDAQ:RARE)

Ultragenyx Announces Positive Data from Phase 1/2 Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia

GlobeNewswire September 4, 2019

GeneTx and Ultragenyx Announce Orphan Drug Designation and Rare Pediatric Disease Designation for GTX-102

GlobeNewswire September 3, 2019

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire August 30, 2019

Ultragenyx Announces Partnership with GeneTx to Advance Treatment for Angelman Syndrome

GlobeNewswire August 14, 2019

Ultragenyx to Present at Wedbush PacGrow Healthcare Conference

GlobeNewswire August 13, 2019

Ultragenyx Reports Second Quarter 2019 Financial Results and Corporate Update

GlobeNewswire August 1, 2019

Ultragenyx Announces Submission of New Drug Application to FDA for UX007 (triheptanoin) for Treatment of Long-Chain Fatty Acid Oxidation Disorders

GlobeNewswire August 1, 2019

Ultragenyx to Host Conference Call for Second Quarter 2019 Financial Results and Corporate Update

GlobeNewswire July 23, 2019

Evolus Expands Board of Directors with Appointment of Independent Directors Peter Farrell, Ph.D. and Karah Parschauer, J.D.

GlobeNewswire July 15, 2019

Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases

GlobeNewswire June 19, 2019

Ultragenyx Expands Leadership Team and Promotes Erik Harris to Chief Commercial Officer

GlobeNewswire June 17, 2019

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire May 31, 2019

Ultragenyx Announces Emil D. Kakkis, M.D., Ph.D. as Recipient of BIO's 2019 Henri A. Termeer Biotechnology Visionary Award

GlobeNewswire May 29, 2019

Ultragenyx to Present at Bank of America Merrill Lynch Healthcare Conference

GlobeNewswire May 10, 2019

Ultragenyx Reports First Quarter 2019 Financial Results and Corporate Update

GlobeNewswire May 6, 2019

Ultragenyx to Host Conference Call for First Quarter 2019 Financial Results and Corporate Update

GlobeNewswire April 30, 2019

Ultragenyx to Present Corporate Update at Analyst and Investor Day on April 17 in New York

GlobeNewswire April 11, 2019

Ultragenyx Announces Approval of Crysvita® (burosumab) in Brazil for the Treatment of X-linked Hypophosphatemia (XLH) in Adults and Children

GlobeNewswire March 26, 2019

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire March 11, 2019

Ultragenyx Announces Pricing of Public Offering of Common Stock

GlobeNewswire February 26, 2019